AKER - Akers Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
3.4400
-0.0600 (-1.71%)
At close: 4:00PM EDT

3.4700 +0.03 (0.87%)
After hours: 6:40PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close3.5000
Open3.5700
Bid3.4200 x 1000
Ask3.4900 x 800
Day's Range3.3300 - 3.5700
52 Week Range1.5500 - 16.3200
Volume800,590
Avg. Volume2,523,748
Market Cap21.061M
Beta (5Y Monthly)0.38
PE Ratio (TTM)N/A
EPS (TTM)-6.2940
Earnings DateAug 13, 2020 - Aug 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Akers Biosciences Closes $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced the closing of its previously announced registered direct offering of an aggregate of 1,366,856 shares of the Company’s common stock, at a purchase price of $3.53 per share priced at-the-market under Nasdaq rules. The gross proceeds to the Company from this offering was approximately $4.8 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The shares of common stock were offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-234449) previously filed with the Securities and Exchange Commission (the "SEC") on November 1, 2019, and declared effective by the SEC on April 7, 2020.

  • TheStreet.com

    Microcap Akers Biosciences Spikes on Covid-Vaccine Progress

    Akers and Premas Biotech are three steps into a four-step plan that could lead to clinical trials of a vaccine candidate.

  • GlobeNewswire

    Akers Biosciences Announces $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 1,366,856 shares of the Company’s common stock, at a purchase price of $3.53 per share, in a registered direct offering priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $4.8 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.

  • GlobeNewswire

    Akers Biosciences and Premas Biotech Announce Successful Completion of Vaccine Prototype & Obtained First Images of VLP

    Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that Premas Biotech, its partner in the development of a vaccine candidate that is seeking to address the COVID-19 pandemic, has successfully completed its vaccine prototype. Premas obtained transmission electron microscopic (TEM) images of the recombinant virus like particle (VLP) assembled in yeast during the past week which marks a significant milestone and is believed by Premas to be one of the first in the world for VLP of SARS-CoV-2 virus. Premas, which is primarily responsible for the development of the vaccine candidate through proof of concept, is collating data at this time and, collectively with Akers, moving forward with conversations with regulatory authorities in India and continuing to develop a regulatory strategy in the United States.

  • Newsfile

    Here's How Akers Biosciences and Premas Biotech Plan To Knock Out COVID-19 Virus; Company Halfway Through Four Milestone Plan

    New York, New York--(Newsfile Corp. - April 24, 2020) - Akers Biosciences (NasdaqCM: AKER) announced a licensing agreement with Premas Biotech to find an effective vaccine for COVID-19. Premas Biotech has over 125 employees and has delivered over 650 proteins and has completed over 240 separate projects for pharmaceutical companies. The company also has four candidates currently in clinical trials globally, and most notable, an oral insulin drug candidate which recently completed a Phase ...

  • Akers Biosciences plans $4.6M stock sale, advances COVID-19 vaccine candidate
    American City Business Journals

    Akers Biosciences plans $4.6M stock sale, advances COVID-19 vaccine candidate

    Akers Biosciences Inc., a South Jersey medical device company that recently joined the race to develop a COVID-19 vaccine, plans to raise $4.6 million in a public stock sale. The Thorofare-based company is selling 766,667 shares of its common stock at a purchase price of $6.00 per share, according to documents filed with the Securities and Exchange Commission. Last month, Akers entered into an in-licensing and product development deal for a coronavirus vaccine candidate under development by Premas Biotech.

  • Akers Says It's Halfway Through Plan To Develop COVID-19 Vaccine Candidate
    Benzinga

    Akers Says It's Halfway Through Plan To Develop COVID-19 Vaccine Candidate

    Akers Biosciences Inc (NASDAQ: AKER), which said earlier this week that it is one step closer to identifying a coronavirus vaccine candidate, announced another successful milestone Wednesday in its vaccine development program.The New Jersey-based company said that it, along with developmental partner Premas Biotech, has successfully completed the second milestone of successful expression of the three coronavirus antigens -- spike, envelop and membrane --selected for their vaccine candidate.Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter."The antigens have been expressed using the D-CryptTM platform at Premas Biotech, which utilizes its vectors and S cerevisiae strain," according to Akers. Premas will now move ahead with purification and post-expression processing that will lead to a scaling up of the antigen, according to a press release. The company is now halfway through a four-milestone plan that it believes will lead to the commencement of clinical trials, Akers Executive Chairman Christopher Schreiber said in a statement. Akers shares were advancing 6.14% to $6.05 at the time of publication Wednesday. Related Links:Analyst Projects Over 130% Upside In This Biopharma Teva Analyst Says Shares Are Pricing In Too Much Risk See more from Benzinga * The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index * The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Akers Biosciences and Premas Biotech Announce Successful Expression of Coronavirus Antigens

    Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed a second milestone, the successful expression of the three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M), that were selected for their vaccine candidate. The antigens have been expressed using the D-CryptTM platform at Premas Biotech, which utilizes its vectors and S cerevisiae strain. Premas is now moving forward with purification and post-expression processing, which we believe should lead to a scaling up of the antigens.

  • GlobeNewswire

    Akers Biosciences Announces $4.6 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 766,667 shares of the Company’s common stock, at a purchase price of $6.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The gross proceeds to the Company from this offering are expected to be approximately $4.6 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.

  • GlobeNewswire

    Akers Biosciences and Premas Biotech Announce Progress in its Vaccine Development for Covid-19

    Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that its collaboration with Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike (S), Envelope (E), and Membrane (M) that they have selected for their vaccine candidate. Premas Biotech develops novel technologies and partners with global biopharmaceutical companies to build and develop novel biotherapeutic & vaccine candidates.

  • South Jersey company's stock closes up 22% after coronavirus vaccine deal
    American City Business Journals

    South Jersey company's stock closes up 22% after coronavirus vaccine deal

    The point-of-care test kit company has in-licensed an experimental vaccine under development for the coronavirus.

  • GlobeNewswire

    Akers Biosciences Schedules Conference Call to Discuss Licensing Announcement with Premas Biotech for a Coronvirus Vaccine Candidate

    Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced it will hold a conference call to discuss the licensing announcement with Premas Biotech for a Coronvirus vaccine candidate. Global biotech executive, co-founder and managing director at Premas, Dr. Prabuddha Kundu M.D., will discuss the process underway to seek fast track development of a vaccine candidate and related milestones that we hope to achieve and plan to announce as we progress. To access the replay, please dial 1-844-512-2921 in the U.S. and 1-412-317-6671 for international callers.

  • GlobeNewswire

    Akers Biosciences Acquires Licenses to Coronavirus Vaccine Candidate from Premas Biotech

    Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that it has acquired a licensing agreement with Premas Biotech, under which Akers will in-license a novel coronavirus vaccine candidate under development by Premas using Premas’ genetically engineered S. cerevisiae platform, D-Crypt™, and partner with Premas to ultimately seek FDA approval. The current global crisis has created the potential for an expedited review process from the FDA, which has recently noted its willingness to fast-track human clinical trials for certain coronavirus candidates.

  • GlobeNewswire

    Akers Biosciences, Inc. Provides Notice of Proposed Settlement of Derivative Litigation

    Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that it reached a settlement agreement to settle two shareholder derivative actions: Watts v. Gormally, et al., No. 2:18-15992 (D.N.J.) and Chan v. Gormally, et al., No. 2:19-cv-4989 (D.N.J.). As previously reported, on October 2, 2019, the plaintiffs filed a motion for preliminary approval of the settlement. On January 8, 2020, the court entered an order that, among other things, granted preliminary approval of the settlement, approved the form and content of the parties' proposed notice of the settlement, directed the Company to issue a press release containing the information in that notice by today, and scheduled a hearing on May 28, 2020 to consider final approval of the settlement.

  • GlobeNewswire

    Akers BioSciences Regains Compliance with Nasdaq Listing Standards

    Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, announced today that on December 10, 2019, it received notice from the Hearings Advisor of the Nasdaq Office of General Counsel that the Company successfully regained compliance with the minimum bid price requirements set forth under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market and that the Company is in compliance with all other applicable listing standards.

  • ACCESSWIRE

    Akers Biosciences to Present at the Investor Summit on December 17th in Philadelphia

    THOROFARE, NJ / ACCESSWIRE / December 10, 2019 / Akers Biosciences, Inc. (NASDAQ:AKER), will be presenting at this year's Investor Summit on December 17 th in Philadelphia. The Investor Summit will take ...

  • GlobeNewswire

    Akers BioSciences, Inc. Announces Closing of Approximately $8 Million Public Offering

    Akers Biosciences, Inc. (the “Company” or “we”) (AKER), a developer of rapid health information technologies, today announced the closing of its previously announced public offering of 613,500 common units at a public offering price of $4.00 per unit and 1,376,500 pre-funded units at a public offering price of $3.9999 per pre-funded unit, raising gross proceeds of $7.96 million, before deducting placement agent’s fees and other estimated offering expenses payable by Akers, assuming none of the preferred stock warrants issued in this offering are exercised. H.C. Wainwright & Co. is acted as exclusive placement agent for the offering. Each unit sold in this offering is comprised of one share of common stock and one preferred stock warrant to purchase one share of Series C Convertible Preferred Stock.

  • GlobeNewswire

    Akers Biosciences to Attend Hemp Industry Daily Forum in Las Vegas, Nevada

    Akers Biosciences, Inc. (the “Company”) (AKER), a developer of rapid health information technologies, today announced that Executive Chairman Christopher Schreiber will attend the “Hemp Industry Daily Forum” on Tuesday, December 10, 2019 as part of MJBizCon Week at the Las Vegas Convention Center in Las Vegas, Nevada. Akers Advisory Board member Bob Hoban is a featured speaker presenting on “International Opportunities” for Hemp operations within the Textiles to Cannabidiol (CBD) space.

  • Benzinga

    The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Dec. 5) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD )(presented ...

  • South Jersey medical device maker raising $8M through stock offering
    American City Business Journals

    South Jersey medical device maker raising $8M through stock offering

    The company, which develops and markets point-of-care diagnostic products, is continuing to evaluate 'strategic business alternatives.'

  • GlobeNewswire

    Akers BioSciences, Inc. Announces Pricing of Approximately $8 Million Public Offering

    Akers Biosciences, Inc. (the “Company” or “we”) (AKER), a developer of rapid health information technologies, today announced the pricing of a public offering of 1,990,000 units. Each unit is comprised of one share of common stock (or common stock equivalent) and one preferred stock warrant to purchase one share of Series C Convertible Preferred Stock. The units are being offered at a public offering price of $4.00 per unit.

  • GlobeNewswire

    Akers Biosciences Continues Strategic Review; Explores Leveraging its 30-years of Laboratory Operations to Enter into the Hemp and Minor Cannabinoid Processing Industry

    Akers Biosciences, Inc. (the “Company” or “we”) (AKER), a developer of rapid health information technologies, today announced that it will continue its strategic review and has identified the hemp and minor cannabinoid sectors as promising adjacent opportunities that could benefit from Akers’ core competencies. The company is exploring how to leverage its 30 years of operational history in its medical device business, where its current products have U.S. Food and Drug Administration (FDA) clearance, its current operations practice Good Manufacturing Processes (cGMP), its medical device facility is certified under ISO 13485 – 2016 and the facility carries an Analytical Lab Certification for Schedules 2, 3, 4 and 5 controlled substances issued by the U.S. Drug Enforcement Administration (DEA) and the State of New Jersey.

  • GlobeNewswire

    Akers Biosciences, Inc. Announces One-for-Twenty Four Reverse Stock Split

    THOROFARE, N.J., Nov. 22, 2019 -- Akers Biosciences, Inc. (NASDAQ: AKER), (“Akers Bio” or the "Company"), a developer of rapid health information technologies, today announced.

  • GlobeNewswire

    AKER: Final Settlement Hearing Rescheduled to December 20, 2019

    NEW YORK, Sept. 25, 2019 -- The Rosen Law Firm, P.A. announces that the hearing to determine whether to approve a proposed class action settlement that would benefit purchasers.

  • GlobeNewswire

    Akers Biosciences Reports Q2 2019 Earnings

    Akers Biosciences, Inc. (AKER) (“Akers Bio” or the “Company”), a developer of rapid health information technologies, reported its financial results for the three and six months ended June 30, 2019. At June 30, 2019, Akers Bio had cash, restricted cash and marketable securities of $4.39 million. The Board of Directors’ process remains underway to evaluate strategic alternatives to maximize shareholder value.